NCT07261306RecruitingEarly phase 1
Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 23 Jul 2025
- Start date
- 29 Aug 2025
- Primary completion date
- 10 Dec 2025
- Lead sponsor
- Lahore General Hospital
- Diseases
- Psoriasis
- NCT number
- NCT07261306
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 75
- From 29 Aug 2025 to the primary completion date, 10 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.
Other illness
- Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.
- Known hypersensitivity or contraindications to either methotrexate or tofacitinib.
- History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.
Other
- Pregnant or lactating women will not be eligible for the study.
Who the study is looking for
- Patients aged 18- 70 years of either gender.
- Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
- Duration of plaque psoriasis for at least 6 months prior to the study.
- Psoriasis that has not shown adequate response to topical therapies
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lahore General Hospital Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.